Lori B. Tucker

Lori B. Tucker

Auto-generated profile, based on publicly available information

Lori B. Tucker

British Columbia Children's Hospital Vancouver British Columbia Canada

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2015 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
JGJaime Guzman
Jaime Guzman
KOKiem Oen
Kiem Oen
LTLori B Tucker
Lori B Tucker
AHAdam M Huber
Adam M Huber
NSNatalie Shiff
Natalie Shiff
CCClaire St. Cyr
Claire St. Cyr
Objective To describe clinical outcomes of juvenile idiopathic arthritis (JIA) in a prospective inception cohort of children managed with contemporary treatments. Methods Children newly diagnosed with JIA at 16 Canadian paediatric rheumatology centres from 2005 to 2010 were included. Kaplan–Meier survival curves for each JIA category were used to estimate probability of ever attaining an active joint count of 0, inactive disease (no active joints, no extraarticular manifestations and a physician global assessment of disease activity <10 mm), disease remission (inactive disease >12 months after discontinuing treatment) and of receiving specific treatments. Results In a cohort of 1104 children, the probabilities of attaining an active joint count of 0 exceeded 78% within 2 years in all JIA categories. The probability of attaining inactive disease exceeded 70% within 2 years in all categories, except for RF-positive polyarthritis (48%). The probability of discontinuing treatment at least once was 67% within 5 years. The probability of attaining remission within 5 years was 46–57% across JIA categories except for polyarthritis (0% RF-positive, 14% RF-negative). Initial treatment included joint injections and non-steroidal anti-inflammatory drugs for oligoarthritis, disease-modifying antirheumatic drugs (DMARDs) for polyarthritis and systemic corticosteroids for systemic JIA. Conclusions Most children with JIA managed with contemporary treatments attain inactive disease within 2 years of diagnosis and many are able to discontinue treatment. The probability of attaining remission within 5 years of diagnosis is about 50%, except for children with polyarthritis.

1 January 1999 in The Journal of Pediatrics
Verified
Journal Article
Closed access
DCDavid A. Cabral
David A. Cabral
LTLori B. Tucker
Lori B. Tucker

29 July 2010 in Journal of Medical Internet Research
Verified
Journal Article
Open access
Jennifer StinsonJennifer Stinson
Jennifer Stinson
PMPatrick McGrath
Patrick McGrath
EHEllen Hodnett
Ellen Hodnett
BFBrian Feldman
Brian Feldman
CDCiaran Duffy
Ciaran Duffy
MWMeghan White
Meghan White
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet

1 October 2012 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Closed access
ABAlan M. Borowoy
Alan M. Borowoy
JPJanet E. Pope
Janet E. Pope
ESEarl Silverman
Earl Silverman
PFPaul R. Fortin
Paul R. Fortin
CPChristian Pineau
Christian Pineau
CPChristine Peschken
Christine Peschken

6 July 2013 in International Journal of Adolescent Medicine and Health
Verified
Journal Article
Closed access
Jennifer StinsonJennifer Stinson
Jennifer Stinson
SKSara Ahola Kohut
Sara Ahola Kohut
LSLynn Spiegel
Lynn Spiegel
MWMeghan White
Meghan White
NGNavreet Gill
Navreet Gill
MKMiriam Kaufman
Miriam Kaufman
Background: The transition from pediatric to adult health care can be challenging for adolescents with chronic illnesses. As a result, many adolescents are unable to transfer to adult health care successfully. Adequate measurement of transition readiness and transfer satisfaction with disease management is necessary in order to determine areas to target for intervention towards improving transfer outcomes. Objectives: This study aims to systematically review and critically appraise research on transition readiness and transfer satisfaction measures for adolescents with chronic illnesses as well as to assess the psychometric quality of these measures. Methods: Electronic searches were conducted in MEDLINE, EMBASE, CINAHL, PsychINFO, ERIC, and ISI Web of Knowledge for transition readiness and transfer satisfaction measures for adolescents with chronic health conditions. Two reviewers independently selected articles for review and assessed methodological quality. Results: In all, eight readiness and six satisfaction measures met the inclusion criteria, for a total of 14 studies, which were included in the final analysis. None of these measures have well-established evidence of reliability and validity. Most of the measures were developed ad hoc by the study investigators, with minimal to no evidence of reliability and/or validity using the Cohen criteria and COSMIN checklist. Conclusion: This research indicates a major gap in our knowledge of transitional care in this population, because there is currently no well-validated questionnaire that measures readiness for transfer to adult health care. Future research must focus on the development of well-validated transition readiness questionnaires, the validation of existing measures, and reaching consensus on outcomes of successful transfer.

1 June 2016 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
JGJaime Guzman
Jaime Guzman
KOKiem Oen
Kiem Oen
AHAdam M Huber
Adam M Huber
KDKaren Watanabe Duffy
Karen Watanabe Duffy
GBGilles Boire
Gilles Boire
RIReACCh-Out investigators
ReACCh-Out investigators
Objective To describe probabilities and characteristics of disease flares in children with juvenile idiopathic arthritis (JIA) and to identify clinical features associated with an increased risk of flare. Methods We studied children in the Research in Arthritis in Canadian Children emphasizing Outcomes (ReACCh-Out) prospective inception cohort. A flare was defined as a recurrence of disease manifestations after attaining inactive disease and was called significant if it required intensification of treatment. Probability of first flare was calculated with Kaplan–Meier methods, and associated features were identified using Cox regression. Results 1146 children were followed up a median of 24 months after attaining inactive disease. We observed 627 first flares (54.7% of patients) with median active joint count of 1, physician global assessment (PGA) of 12 mm and duration of 27 weeks. Within a year after attaining inactive disease, the probability of flare was 42.5% (95% CI 39% to 46%) for any flare and 26.6% (24% to 30%) for a significant flare. Within a year after stopping treatment, it was 31.7% (28% to 36%) and 25.0% (21% to 29%), respectively. A maximum PGA >30 mm, maximum active joint count >4, rheumatoid factor (RF)-positive polyarthritis, antinuclear antibodies (ANA) and receiving disease-modifying antirheumatic drugs (DMARDs) or biological agents before attaining inactive disease were associated with increased risk of flare. Systemic JIA was associated with the lowest risk of flare. Conclusions In this real-practice JIA cohort, flares were frequent, usually involved a few swollen joints for an average of 6 months and 60% led to treatment intensification. Children with a severe disease course had an increased risk of flare.